| NCT06858696 | A Study to Investigate Pharmacokinetics (PK) and Safety of a Single Dose of Mavorixafor in Participants With Hepatic Impairment (HI) Compared to Matched Healthy Volunteers With Normal Hepatic Function | RECRUITING | PHASE1 | 2025-02-28 | 2026-04 | 2026-03 |
| NCT06914869 | Drug-Drug Interaction Potential of Mavorixafor | COMPLETED | PHASE1 | 2025-02-18 | 2025-05-19 | 2025-05-19 |
| NCT06056297 | A Study of Mavorixafor in Participants With Congenital and Acquired Primary Autoimmune and Idiopathic Chronic Neutropenic Disorders Who Are Experiencing Recurrent and/or Serious Infections | RECRUITING | PHASE3 | 2024-06-06 | 2026-08 | 2026-07 |
| NCT04154488 | A Study of Mavorixafor in Participants With Congenital Neutropenia and Chronic Idiopathic Neutropenia Disorders | COMPLETED | PHASE1, PHASE2 | 2021-10-16 | 2024-08-27 | 2024-08-27 |
| NCT04274738 | A Study of Mavorixafor in Combination With Ibrutinib in Participants With Waldenstrom's Macroglobulinemia (WM) Whose Tumors Express Mutations in MYD88 and CXCR4 | COMPLETED | PHASE1 | 2020-04-30 | 2022-10-31 | 2022-10-31 |
| NCT03995108 | Efficacy and Safety Study of Mavorixafor in Participants With Warts, Hypogammaglobulinemia, Infections, and Myelokathexis (WHIM) Syndrome | ACTIVE_NOT_RECRUITING | PHASE3 | 2019-10-24 | 2025-12 | 2025-12 |
| NCT02923531 | Addition of X4P-001 to Nivolumab Treatment in Participants With Renal Cell Carcinoma | TERMINATED | PHASE1, PHASE2 | 2016-12-07 | 2018-08-08 | 2018-08-08 |
| NCT03005327 | A Dose Determination and Safety Study of X4P-001 (Mavorixafor) in Participants With Warts, Hypogammaglobulinemia, Infections, and Myelokathexis (WHIM) Syndrome | COMPLETED | PHASE2 | 2016-12 | 2022-06-16 | 2022-06-16 |
| NCT02823405 | X4P-001 and Pembrolizumab in Patients With Advanced Melanoma | COMPLETED | PHASE1 | 2016-09-15 | 2018-03-15 | 2018-03-15 |
| NCT02667886 | Trial of X4P-001 in Participants With Advanced Renal Cell Carcinoma | COMPLETED | PHASE1, PHASE2 | 2016-04-27 | 2022-04-14 | 2022-04-14 |
| NCT02680782 | A Study Comparing Once-Daily vs. Twice-Daily Dosing of X4P-001 in Healthy Volunteers | TERMINATED | PHASE1 | 2016-01-12 | 2016-02-28 | 2016-02-28 |